Led and managed a multidisciplinary global team of over 90 technical staff covering diverse areas from women’s health care, infectious diseases, and health systems to innovation, digital health and impact measurement; ensured technical excellence and accelerated impact across the 43 countries where Jhpiego works. Provided visionary and strategic leadership as a member of the Leadership Team during a pivotal time, shaping Jhpiego's strategy to embrace significant sector transformations and align for growth.

Explored strategic investments in, and financing vehicles for, digital technologies and data analytics – from digital health and machine learning to blockchain and robotics – to unlock their potential to help tackle humanity’s toughest challenges; initial work focusing on advancing opportunities in two areas: (1) building next generation disease surveillance systems for pandemic threats that predict outbreaks before they occur, detect them earlier, and provide enhanced decision support for a more rapid and robust response and (2) identifying transformational data technology opportunities to strengthen community health.

Advised the Rockefeller Foundation President and leadership in identifying the Foundation's new health priority for the next decade, setting the initial strategy and identifying opportunities for investment.

• Founded and built CII, a center of excellence applying business rigor and disruptive thinking to accelerate the development, introduction and scale-up of priority global health innovations. Built and lead a team of 16, recruiting experts from pharma/medtech and business consulting• Developed and launched three Grand Challenges, including Saving Lives at Birth, Fighting Ebola and Combating Zika and Future Threats, catalyzing $140 million in new investments and a robust pipeline of groundbreaking innovations that are already beginning to scale and save lives • Spearheaded innovative finance deals including a $100 Million working capital fund backed by a USAID guarantee providing bridge financing to accelerate the purchase of health commodities• Catalyzed market incentives to stimulate R&D investment, including $10 Million for Advance Purchase Commitments for Zika diagnostics – a first for the agency • Created multiple public private partnerships and catalyzed licensing deals, including with Coca-Cola, GSK, Bill & Melinda Gates Foundation, DuPont and McCann Health, to strengthen health systems and accelerate access to life-saving commodities • Drove the creation of multiple guides and actionable tools that capture and help institutionalize state-of-the-art practices needed to successfully scale innovationsCII Director Jan 2012-Jan 2017Senior Advisor for Partnerships and Innovation July 2010-Dec 2011

• Managed and coordinated the activities of Malaria No More’s international affiliates; developed and negotiated MOUs for MNM’s affiliates clarifying roles and responsibilities and use of the MNM brand; established international trademark protections for MNM and identified and evaluated opportunities for expansion of MNM to other countries • Led global advocacy for MNM, developing the advocacy strategy to guide the organization’s activities and those of its affiliates; honed malaria advocacy messages and identified innovative financing mechanisms to support funding for malaria control

• Founded BVGH, established the Board of Directors, and led the organization’s initial growth, strategy and operations, serving as the Executive Director for the first two years• Raised nearly $15 million in funding from the Bill & Melinda Gates Foundation, Rockefeller Foundations and corporate donors • Developed BVGH’s policy and advocacy agenda centered around the need for new market incentives to stimulate industry investment in global health R&D, including building industry support for advance market commitments and leading a multi-stakeholder group to ensure the successful implementation of the Priority Review Voucher Program, working closely with FDA and Congressional staff• Offered a business approach to global health solutions, revealing to companies where opportunities in global health can have financial promise, including leading development of the TB Vaccine Business Case, articulating a viable market for TB vaccines, and promoted to targeted companies – actions spurred several companies to start new TB programs • Built relationships among and across multiple constituencies, establishing BVGH as a respected, independent intermediary between the biopharmaceutical industry and global health community

• Established and led BIO’s Global Health CEO Committee, evaluating incentives to address barriers to global health product development• Conceived of and wrote the business plan for BIO Ventures for Global Health and helped secure the BIO Board’s approval to spin out a new organization• Planned and organized BIO and the Gates Foundation Partnering for Global Health Forum 2002 – the first global health meeting bringing together the biotech industry and the global health community to jointly tackle the challenge of addressing diseases of the developing world• Led BIO’s discussions with the FDA to secure the successful reauthorization of the Prescription Drug User Fee Act (PDUFA III); developed BIO’s policy proposals and secured Board approval • Established and led a BIO task force to address the reorganization of biologics within the FDA; developed position paper articulating industry’s recommendations on best practices at the agency; led discussions with FDA officials to communicate those recommendations• Established and led BIO’s Regulatory Affairs Committee

• Served as Special Assistant to several OMB officials under the Clinton White House• Developed and coordinated policy positions with OMB, White House, and agency officials including the FDA, CDC and NIH; briefed and advised senior administration officials on highly visible and politically sensitive regulatory and policy issues; managed daily activities of the branch and provided guidance to analysts; managed the budget and oversaw all personnel decisions for the division• Negotiated agreement between FDA and the Department of Defense regarding administration of investigational drugs to US troops in combat situations; developed Presidential Executive Order ensuring sufficient protections for troops • Negotiated with agency officials and Congress to enact FDA Modernization Act (FDAMA) and worked closely with FDA to ensure successful implementation of numerous FDAMA regulations• Led OMB coordination of Federal food safety activities and contributed significantly to the Administration’s achievements under the Food Safety Initiative• Negotiated significant changes to various labeling regulations including FDA’s over-the-counter and prescription drug labeling rules